Anadys culls staff and clinical programmes
This article was originally published in Scrip
Anadys Pharmaceuticals will cut 40% of its staff and halt development on two thirds of its clinical pipeline as the US firm seeks additional cash from investors. The restructuring will save Anadys around $4-5 million annually at the cost of approximately 20 jobs.
You may also be interested in...
AB Science has closed its IPO at just half of the value of its initial expectations. The gross proceeds of the French firm's offer were €27.5 million, compared with the €55.5 million it anticipated when it filed for the offering on 8 April. Of the total, the company secured $16.5 million from the sale of newly issued shares; the remaining €11 million went to selling shareholders.
Amgen's sales rebounded in the first quarter rising 9% to $3.6 billion after a disappointing end to last year. However, the introduction of new legislation for US healthcare has weighed on its forecast for the year, as it has done for many of its competitors.
Gilead Sciences has reported a 24% increase in product sales to $1.8 billion for the first quarter following strong growth of its antiviral franchise. Net income was $855 million, an increase of 45%.